Health‐related quality of life in patients with esophageal cancer or precancerous lesions assessed by EQ‐5D: A multicenter cross‐sectional study. Issue 4 (4th March 2020)

• Record Type: Journal Article
• Authors: Wang, Youqing; Shi, Jufang; Du, Lingbin; Huang, Huiyao; Wang, Le; Zhu, Juan; Li, Huizhang; Bai, Yana; Liao, Xianzhen; Mao, Ayan; Liu, Guoxiang; Ren, Jiansong; Sun, Xiaojie; Gong, Jiyong; Zhou, Qi; Mai, Ling; Zhu, Lin; Xing, Xiaojing; Liu, Yuqin; Ren, Ying; Song, Bingbing; Lan, Li; Zhou, Jinyi; Lou, Peian; Sun, Xiaohua; Qi, Xiao; Wu, Shouling; Wei, Wenqiang; Zhang, Kai; Dai, Min; Chen, Wanqing; He, Jie;
• Is Part Of: Thoracic cancer. Volume 11:Issue 4(2020)
• Page Start: 1076
• Page End: 1089
• Publication Date: 2020-03-04
• Subjects: EQ‐5D‐3L -- esophageal cancer -- health state utility -- health‐related quality of life -- multivariable linear regression; Chest -- Cancer -- Periodicals; Chest -- Cancer -- Treatment -- Periodicals; Chest -- Surgery -- Periodicals; 616.99494005
• DOI: 10.1111/1759-7714.13368
• Languages: English
• ISSNs: 1759-7706

Abstract

Abstract : Background: We aimed to obtain a set of health state utility scores of patients with esophageal cancer (EC) and precancerous lesions in China, and to explore the influencing factors of health‐related quality of life (HRQoL). Methods: A hospital‐based multicenter cross‐sectional study was conducted. From 2013 to 2014, patients with EC or precancerous lesions were enrolled. HRQoL was assessed using a European quality of life‐5 dimension (EQ‐5D‐3L) instrument. Multivariable linear regression analysis was performed to explore the influencing factors of the EQ‐5D utility scores. Results: A total of 2090 EC patients and 156 precancer patients were included in the study. The dimension of pain/discomfort had the highest rate of self‐reported problems, 60.5% in EC and 51.3% in precancer patients. The mean visual analog scale (VAS) score for EC and precancer patients were 68.4 ± 0.7 and 64.5 ± 3.1, respectively. The EQ‐5D utility scores for EC and precancer patients were estimated as 0.748 ± 0.009 and 0.852 ± 0.022, and the scores of EC at stage I, stage II, stage III, and stage IV were 0.693 ± 0.031, 0.747 ± 0.014, 0.762 ± 0.015, and 0.750 ± 0.023, respectively. According to the multivariable analyses, the factors of region, occupation, household income in 2012, health care insurance type, pathological type, type of therapy, and time points of the survey were statistically associated with the EQ‐5D utility scores of EC patients. Conclusions: There were remarkable decrements of utility scores among esophageal cancer patients, compared with precancer patients. The specific utility scores of EC would support further cost‐utility analysis in populations in China.